Positive results from phase I clinical trial of SMT D002 for the treatment of Seborrhoea

SMT D002 suppresses sebum levels by 90% in repeat-dose trial

22-Apr-2008

Summit Corporation plc announced a positive outcome from its repeat-dose Phase I clinical trial of SMT D002, its candidate for the treatment of seborrhoea (excessive sebum production), a primary cause of acne.

The study was conducted in 18 healthy volunteers and examined the effect of repeat oral doses of SMT D002 over a four-day period. The key findings of the Phase I clinical trial are:

- Statistically significant levels of sebum suppression (primary endpoint) of 90% when compared to the placebo group (p=0.04)

- SMT D002 proved to be safe with no serious or unexpected adverse side-effects reported

- Sebum levels measured over six hours following treatment using a Sebumeter, an industry accepted method

- Results from trial support a previous positive Phase I single-dose study conducted in nine volunteers

The results of this trial confirm the potential of SMT D002 as a new therapeutic agent for the treatment of seborrhoea in acne patients. Summit plans to develop a topical formulation of SMT D002 to further evaluate its efficacy in the treatment of acne and the Company is actively seeking a commercial partner to advance this candidate from the clinic through to the market.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Infrareal takes over pharmaceutical and biotech site in Orth, Lower Austria from Takeda - "Our expertise will help us to further expand the site, and we are hoping to attract more companies from these industrie"

Infrareal takes over pharmaceutical and biotech site in Orth, Lower Austria from Takeda - "Our expertise will help us to further expand the site, and we are hoping to attract more companies from these industrie"

Sanofi Pasteur and Butantan Institute to Provide A(H1N1) Vaccine to Brazilian Government - Initial supply of 18 million doses of A(H1N1) influenza vaccine

A Trojan Horse delivery for treating a rare, potentially deadly, blood-clotting disorder - In this possible treatment, platelet blood cells carry an enzyme needed to prevent clots in TTP, while hiding the enzyme from autoantibody neutralization

CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform

Novel HCMV compound of AiCuris in phase IIb trial with bone marrow transplant recipients

Basilea receives milestone payment from distribution agreement for Toctino with Almirall

Biotage AB and McMaster University sign joint agreement to develop new chemistry platform

Asia-Pacific continues to drive global healthcare investment, innovation and growth ASEAN - A US$150 billion healthcare market by 2017, says Frost & Sullivan

Pharmacogenomics study finds rare gene variants critical for personalized drug treatment

Cambridge-based Startup Develops World’s Fastest Coronavirus-Killing Antiviral Protection

Cambridge-based Startup Develops World’s Fastest Coronavirus-Killing Antiviral Protection

Evolva shareholders approve all Board proposals in AGM: Green light for Abunda acquisition

Aragen Bioscience, Inc. and CEVEC Sign License Agreement for Human CAP and CAP-T Technology